This document outlines a 7-step approach to evaluating musculoskeletal pain: 1) Determine if the pain is articular or non-articular, 2) Distinguish between arthralgia and arthritis, 3) Assess if the condition is acute or chronic, 4) Identify if it is inflammatory or non-inflammatory arthritis, 5) Determine if it is monoarticular or polyarticular, 6) Examine the distribution pattern and whether it is symmetrical or asymmetrical, and 7) Look for any extra-articular manifestations. A thorough history and physical exam can provide 80-95% of diagnostic information needed, while imaging and labs only contribute 5%. Certain "red flag" diagnoses like infection require prompt diagnosis and
This presentation focuses on different types of arthritis/joint disorders. It provides stepwise approach to evaluation and diagnoses and it's truly wonderful to have a broad overview of many joint conditions in one presentation - ranging from osteoarthritis, gout, rheumatoid arthritis, septic arthritis, to ankylosing spondilitis, and many others, including fibromyaligia.
Arthritis is a large topic, and almost everyone who has a bone will develop some forms of arthritis at some point in their lives. This presentation addresses many types of arthritis, including osteoarthritis, septic arthritis, gout, rheumatoid arthritis and so forth.
This presentation focuses on different types of arthritis/joint disorders. It provides stepwise approach to evaluation and diagnoses and it's truly wonderful to have a broad overview of many joint conditions in one presentation - ranging from osteoarthritis, gout, rheumatoid arthritis, septic arthritis, to ankylosing spondilitis, and many others, including fibromyaligia.
Arthritis is a large topic, and almost everyone who has a bone will develop some forms of arthritis at some point in their lives. This presentation addresses many types of arthritis, including osteoarthritis, septic arthritis, gout, rheumatoid arthritis and so forth.
An apt yet detailed description of Polyarthritis for undergraduate level with basic definitions, classification, concept, clinical features along with descriptive images, diagnosis & assessment with distinguishing features along with differential diagnosis.
RHEUMATOID ARTHRITIS BY DR BASHIR AHMED DAR ASSOCIATE PROFESSOR MEDICINE SOPO...Prof Dr Bashir Ahmed Dar
Dr Bashir ahmed dar associate professor medicine chinkipora sopore kashmir presently working in medical college malaysia describes rheumatoid arthritis which is a autoimmune disorder in which Immune system identifies the synovial membrane as "foreign" and begins attacking it.
Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of internal Medicine, Immunology, rheumatology and allergy
How to approach a musculoskeletal pain step by step?
Differentiating different rheumatic diseases
An apt yet detailed description of Polyarthritis for undergraduate level with basic definitions, classification, concept, clinical features along with descriptive images, diagnosis & assessment with distinguishing features along with differential diagnosis.
RHEUMATOID ARTHRITIS BY DR BASHIR AHMED DAR ASSOCIATE PROFESSOR MEDICINE SOPO...Prof Dr Bashir Ahmed Dar
Dr Bashir ahmed dar associate professor medicine chinkipora sopore kashmir presently working in medical college malaysia describes rheumatoid arthritis which is a autoimmune disorder in which Immune system identifies the synovial membrane as "foreign" and begins attacking it.
Holistic Approach to rheumatic patients Ahmed Yehia Ismaeel, Lecturer of internal Medicine, Immunology, rheumatology and allergy
How to approach a musculoskeletal pain step by step?
Differentiating different rheumatic diseases
Rheumatoid arthritis (RA) facts
Rheumatoid arthritis is an autoimmune disease that can cause chronic inflammation of the joints and other areas of the body.
It can affect people of all ages.
The cause of rheumatoid arthritis is not known.
In rheumatoid arthritis, multiple joints are usually, affected in a symmetrical pattern.
Urticarial vasculitis diagnostic challenge in 2 cases Ahmed Yehia, MD Immunology, rheumatology and allergy
How to approach a case of itching and urticaria and how to interprete skin biopsy
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the latest guidelines ACR and EULAR, Ahmed Yehia Ismaeel, MD Beni-Suef University
ACR EULAR CLASSIFICATION CRITERIA FOR GOUT
EULAR 2023 Guidelines on gout imaging
ACR guideline recommendations for gout management
The Catastrophe (Anaphylaxis ) Ahmed Yehia, MD, internal medicine, Immunology, rheumatology and allergy, Beni-Suef
EAACI Guidelines
WAO criteria for anaphylaxis
Differential diagnosis of anaphylaxis (Anaphylaxis mimics)
Anaphylaxis action plan
How to identify anaphylaxis etiology?
How to approach a case of proteinuria and differential diagnosis of proteinuria, how to assess protein loss in the kidney
Dr. Abdel Rahman Mansy, Beni-Suef University, internal medicine department, nephrology unit
Introduction to GN glomerulonephritis case-based approach
Approach to acute kidney injury and GN diagnostics, classification and differential diagnosis.
Also discussing histopathology basics
Dr. Ahmed Yehia, lecturer of internal medicine, Beni-Suef University
SLE Systemic lupus erythematosus 2022
Basics, updates Prof. Hanan Ali Taha, professor of Internal Medicine and Head of the immunology unit, Faculty of Medicine, Beni-Suef University University
Infective endocarditis ESC guidelines Ahmed Yehia. MD Internal Medicine, Faculty of Medicine, Beni-Suef University
Infective endocarditis criteria
ESC guidelines 2015
Blood culture negative infective endocarditis BCNIE
Prevention of endocarditis
Indications of surgery in IE
Anticoagulant in IE
Pheochromocytoma, Dr. Mahmoud Naiem, internal medicine and endocrinology, overview on diagnosis, investigations, medical and surgical management options, perioperative care
Lupus nephritis update, classification, approach according to guidelines, different case scenarios with stress on algorithmic management of different presentations
Ahmed Yehia
Vitamin d trying to solve the dilemma, when and how to screen? How to replace? Ahmed Yehia, MD internal medicine, clinical immunology, Beni-Suef university
algorithmic case-based approach to classify, diagnose and manage different angioedema types in adults and pediatrics with special attention to the emergency room management
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
2. Goal
The goal of the musculoskeletal
evaluation is to formulate a D.D.
that leads to an accurate
diagnosis and timely therapy,
while avoiding excessive
diagnostic testing and
unnecessary treatment.
3. Not to be missed
•There are several urgent
conditions that must be
diagnosed promptly to avoid
significant morbid or mortal
sequelae . These "red flag"
diagnoses include septic
arthritis, acute crystal-induced
arthritis (e.g., gout), and
fracture. Each may be suspected
by its acute onset and
mon0articular or focal
musculoskeletal pain.
7. • A careful history provides 80% of the diagnostic information.
• Physical examination adds another 15%.
• While Imaging and raboratory together contribute only 5%.
8. • So , don’t request an
investigation unless:
1. You have done a thorough
history and examination.
2. A D.D. exists in your mind ,
3. It will change the plan of
management and
4. You know how to interpret it.
10. Approach to
arthritis can be
classified into 7
steps :
1. Articular or non-articular pain
2. Is it arthralgia or arthritis?
3. Acute or chronic (Duration)
4. Inflammatory or non-
inflammatory
5. Mono or polyarticular (Number)
6. Distribution: Symmetrical or
asymmetrical; with or without
axial involvement
7. Extraarticular manifestations
present or absent
11. Step I: Is it soft-
tissue rheumatism
(STR)? (Articular
or nonarticular
pain)?
•This issue must be
addressed first of
all because (STR) is
the commonest
cause of
musculoskeletal
pain.
13. Feature STR Arthritis
Pain Superficial,
sharply localized
Deep, diffuse
circumferential
Tenderness Localized Circumferential, along joint
line
Active movement Painful in
some directions
Painful in
all directions
Passive
movement
No pain Painful
Synovitis/Effusion Nil Present
Crepitus/Instability/
Deformity
Absent Often present
14. Many presenting with the above (localized
syndromes) may have 1 of the following
generalized disorders:
Fibromyalgia
syndrome (chronic
pain-amplification
syndrome)
Chronic fatigue
syndrome
Benign joint
hypermobility
syndrome (BJHS)
18. Step 4: Is it inflammatory arthritis?
• Inflammatory arthritis is characterised by :
I. Some or all of the 4 cardinal signs of inflammation
(swelling. warmth, pain, erythema)
2, Prolonged early morning stiffness (usually 60 minutes or more)
3, Improvement of symptoms on gentle use of joints.
4. Spontaneously fluctuating course
5. Usually symptoms are worse at night.
6. Constitutional symptoms (fatigability, loss of appetite, loss of weight, low-
grade fever or night sweat)
7. Presence of inflammatory markers:
*High ESR, CRP and platelets
*Reversed A/G ratio *Low haemoglobin *WBC high
*Mild elevation of alkaline phosphatase
19. Inflammatory Mechanical
Stiffness (Morning stiffness) > 60 min. Brief
Swelling, redness, hotness (Synovitis) ++++ -
Systemic manifestations +++ -
Symptoms worsen by Rest Movement
Sedimentation rate (ESR) & CRP +++ Normal
Serology Usually positive Negative
20. Signs of degenerative or mechanical joint disease
• at the distal interphalangeal joints - Heberden nodes,
• at the proximal interphalangeal joints are called Bouchard
nodes.
Bony overgrowth of the joints (osteophytes)-
• intra-articular loose bodies,
• osteophyte formation, or subluxation.
Limited range of motion:
Crepitus during active or passive range of motion
21.
22. Step 5: Number of joints
involved?
Monoarthritis
1 joint
Oligoarthritis
2-4
Polyarthritis
>4
23. Step 5: Number of
joints involved?
Monoarthritis
Acute
Septic until
proven
otherwise
24. Acute Monoarthritis
• This is to be treated as a rheumatological
emergency.
• Urgent synovial fluid examination
mandatory for:
• I. Culture & sensitivity: Pathogens (Gram
staining, bacterial culture)
• 2. Crystals (polarised light microscopy)
• 3. White Cell count
25. Differential
diagnosis of
acute
monoarthritis
I. Septic arthritis
2. Crystal arthropathies
3. Haemorrhagic arthropathies
4. Miscellaneous: Palendromic rheumatism, others
5.Monoarticular onset of chronic inflammatory arthritis
(frequently seen in psoriatic arthritis, may occur in RA
and seronegative inflammatory arthritides)
30. Step 6 : distribution
Symmetric or not
Axial or peripheral
Small or large
Pattern & time-
relation
31.
32.
33.
34.
35. Specific distribution patterns
The distal interphalangeal joints of the
fingers
• involved in psoriatic arthritis, gout, or
osteoarthritis
• spared in RA.
Joints of the lumbar spine
• involved in ankylosing spondylitis
• spared in RA.
37. migratory pattern
• inflammation for only a few days in each
joint (eg, acute rheumatic fever,
disseminated gonococcal infection).
additive or simultaneous pattern
• inflammation persists in involved joints as
new ones become affected.
intermittent pattern
• episodic involvement occurs, with
intervening periods free of joint symptoms
(eg, gout, pseudogout, Lyme arthritis).
41. Step 7:Extra-articular manifestations
• underlying systemic disorder.
• include fatigue, malaise, and weight loss.
Constitutional symptoms
• SLE, dermatomyositis, scleroderma, Lyme disease, psoriasis, Henoch-Schönlein purpura,
and erythema nodosum.
Skin lesions
• Episcleritis and scleritis -RA or Wegener granulomatosis
• anterior uveitis - ankylosing spondylitis,
• iridocyclitis - juvenile RA
• Conjunctivitis -reactive arthritis
Ocular symptoms or signs
42.
43. Red flags.
They can be indicative of any
inflammatory, infective or neoplastic
process:
• Weight loss
• Fever or other systemic manifestation
• Night pain
• Single joint involvement
• Neurological symptoms and signs
44. Approach to arthritis can be classified into 7 steps :
1. Articular or nonarticular pain
2. Is it arthralgia or arthritis?
3. Acute or chronic (Duration) : 6 weeks
4. Inflammatory or non-inflammatory
5. Mono or polyarticular (Number)
6. Symmetrical or asymmetrical; with or
without axial involvement (Distribution)
7. Extraarticular manifestations??